NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
STAVUDINE; LAMIVUDINE; NEVIRAPINE (stavudine; lamivudine; nevirapine) by PharmaIN is 12. Approved for human immunodeficiency virus (hiv)-1 infection [see ].
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (stavudine, lamivudine) and a non-nucleoside reverse transcriptase inhibitor (nevirapine) used to treat HIV-1 infection. The combination works by inhibiting viral reverse transcriptase, reducing HIV replication across multiple enzymatic pathways. This oral tablet formulation is designed for adult and pediatric HIV patients requiring antiretroviral therapy.
PRE_LAUNCH
Pre-launch stage indicates team-building phase for commercial, medical affairs, and regulatory roles; career opportunity lies in establishing market presence in HIV treatment.
Mechanism of Action
12.1 Mechanism of Action Stavudine is an antiviral drug [see ]. 12.3 Pharmacokinetics The pharmacokinetics of stavudine have been evaluated in HIV-1-infected adult and pediatric patients (, , and ). Peak plasma concentrations (C max ) and area under the plasma concentration-time curve (AUC)…
Worked on STAVUDINE; LAMIVUDINE; NEVIRAPINE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.